Dr Subir Basak, president, Drug Discovery Services , Jubilant Life Sciences.
Q: Please tell us in brief about the major strategic alliances that Jubilant has recently struck globally and in India. How will these benefit the company?
Jubilant Life Sciences, an integrated global pharmaceutical and lifesciences company is conducting several collaborative and integrated drug discovery programs. The collaborative or partnership model is an integrated discovery program across single or a portfolio of molecules. Recently, we announced some major collaborations in the Drug Discovery space. Jubilant's fully owned subsidiaries, Jubilant Biosys, Jubilant Clinsys Ltd. and Jubilant Chemsys are engaged in the business of innovative drug discovery and development. Appended below are some of the recent announcements:
Jubilant Biosys and Orion Corporation, the largest pharmaceutical company in Finland, announced a path breaking drug discovery collaboration to discover small molecule inhibitors in the neuroscience therapeutic area. Jubilant Biosys also announced the expansion of Drug Discovery alliance with Janssen Pharmaceutica aimed to deliver preclinical candidates to Janssen.
Jubilant Chemsys, a wholly-owned subsidiary of Jubilant Life Sciences, and one of the most recognized drug discovery research services organizations from Asia announced the extension of its collaborative partnership with Infectious Disease Research Institute (IDRI) for TB drug discovery.
These alliances will help Jubilant in leveraging its drug discovery expertise and enable in strengthening the disease franchises from a scientific perspective. Additionally, we share both the risks and rewards of the project with our collaborators and receive milestone payments on accomplishment of agreed milestones and bonus payments if the milestones are achieved within the time line. In some projects, Jubilant will also be rewarded with royalty on sales if the molecule enters the market.
Q: What are the key areas that Jubilant is currently focusing upon and how is your drug development pipeline in critical disease areas?